Shares in UnitedHealth Group do not show any sign of a slowdown in the ascending dynamic. Investors could bet on a continuation of the underlying trend. Investors have an opportunity to buy the stock and target the $ 220.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
In a short-term perspective, the company has interesting fundamentals.
UnitedHealth Group accounts for 4.86 % of our USA Portfolio. A trade is currently open since 11/02/2015 with a purchase price of $ 119.36. Discover the other 19 stocks of the USA portfolio managed by the 4-traders portfolio management team.
Predictions on business development from analysts polled by Thomson-Reuters are tight. This results from either a good visibility into core activities or accurate earnings releases.
Historically, the company has been releasing figures that are above expectations.
As regards fundamentals, the enterprise value to sales ratio is at 1 for the current period. Therefore, the company is undervalued.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The stock is in a well-established, long-term rising trend above the technical support level at 158.66 USD
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.